Efficacy of high-dose chemotherapy and autologous stem cell transplantation in patients with relapsed medulloblastoma: A report on the Korean Society for Pediatric Neuro-oncology (KSPNO)-S-053 study

Journal of Korean Medical Science

Volumn 25, Issue 8, 2010, Pages 1160-1166

  Park, Jun Eun ^a   Kang, Joseph ^b   Yoo, Keon Hee ^c   Sung, Ki Woong ^c   Koo, Hong Hoe ^c   Lim, Do Hoon ^c   Shin, Hyung Jin ^c   Kang, Hyoung Jin ^d   Park, Kyung Duk ^d   Shin, Hee Young ^d   Kim, Il Han ^e   Cho, Byung Kyu ^e   Im, Ho Joon ^f   Seo, Jong Jin ^f   Park, Hyeon Jin ^g   Park, Byung Kiu ^g   Ahn, Hyo Seop ^d  

^a Ajou University School of Medicine   (South Korea)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

Author keywords

Autologous; Hematopoietic stem cell transplantation; Medulloblastoma; Recurrence; Tandem; Transplantation

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; CEREBELLUM TUMOR; CHILD; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MEDULLOBLASTOMA; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; SALVAGE THERAPY; SOUTH KOREA; TUMOR RECURRENCE;

ADOLESCENT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; REPUBLIC OF KOREA; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77956599660     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.8.1160     Document Type: Article

References (15)

1. Bouffet E, Doz F, Demaille MC, Tron P, Roche H, Plantaz D, Thyss A, Stephan JL, Lejars O, Sariban E, Buclon M, Zucker JM, Brunat-Mentigny M, Bernard JL, Gentet JC. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse? Br J Cancer 1998; 77: 1321-6.
2. Finlay JL, Goldman S, Wong MC, Cairo M, Garvin J, August C, Cohen BH, Stanley P, Zimmerman RA, Bostrom B, Geyer JR, Harris RE, Sanders J, Yates AJ, Boyett JM, Packer RJ. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol 1996; 14: 2495-503.
3. Shih CS, Hale GA, Gronewold L, Tong X, Laningham FH, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M. High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 2008; 112: 1345-53.
4. Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M, Sevilla J, Diaz MA, Madero L. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol 2005; 71: 33-8.
5. Lee SH, Yoo KH, Sung KW, Kim JY, Cho EJ, Koo HH, Chung SE, Kang SW, Oh SY, Ham DI, Kim YD. Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma. Bone Marrow Transplant 2008; 42: 385-91.
6. Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH, Lee SK, Kim J, Lim DH, Suh YL, Kim DW. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant 2007; 40: 37-45.
7. Butturini AM, Jacob M, Aguajo J, Vander-Walde NA, Villablanca J, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, Finlay JL. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Cancer 2009; 115: 2956-63.
8. Grodman H, Wolfe L, Kretschmar C. Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. Pediatr Blood Cancer 2009; 53: 33-6.
9. Foreman NK, Schissel D, Le T, Strain J, Fleitz J, Quinones R, Giller R. A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J Neurooncol 2005; 71: 181-7.
10. Sung KW, Yoo KH, Cho EJ, Koo HH, Lim do H, Shin HJ, Ahn SD, Ra YS, Choi ES, Ghim TT. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 2007; 48: 408-15.
11. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7: 813-20.
12. Fagioli F, Biasin E, Mastrodicasa L, Sandri A, Ferrero I, Berger M, Vassallo E, Madon E. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors. Cancer 2004; 100: 2215-21.
13. Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-oncol 2008; 10: 745-51.
14. Cheuk DK, Lee TL, Chiang AK, Ha SY, Chan GC. Autologous hematopoietic stem cell transplantation for high-risk brain tumors in children. J Neurooncol 2008; 86: 337-47.
15. Rosenfeld A, Kletzel M, Duerst R, Jacobsohn D, Haut P, Weinstein J, Rademaker A, Schaefer C, Evans L, Fouts M, Goldman S. A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. J Neurooncol 2010: 97: 247-55.